GlassScriptPhysician profile
Vicky W Alday
NPI 1306052279
$11,137.41
in general payments reported to CMS, 2019-2025
52 companies · $2,135 in 2025
The $2,135 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,529 · 2022: $2,598 · 2023: $2,277 · 2024: $2,599 · 2025: $2,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,873 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,873.19 |
| Education | $137.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,284.78 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $991.24 | 2021-2025 | Krystexxa, Repatha, Otezla |
| Mallinckrodt Hospital Products INC. | $972.72 | 2021-2025 | Acthar, Terlivaz |
| Novo Nordisk INC | $895.55 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Vifor Pharma, INC. | $687.05 | 2021-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $666.23 | 2021-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $637.33 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $536.85 | 2023-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $517.23 | 2022-2025 | Filspari |
| Ardelyx, INC. | $470.43 | 2023-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $417.58 | 2021-2025 | |
| Lilly USA, LLC | $407.87 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $347.55 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $259.35 | 2022-2025 | Tarpeyo |
| Paratek Pharmaceuticals, INC. | $158.70 | 2023-2025 | Nuzyra |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Alday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.